Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel

Gastroenterology

Volumn 139, Issue 4, 2010, Pages

  Wu, Chun Ying ^a,b,c,d   Chan, Francis Ka Leung ^e   Wu, Ming Shiang ^f   Kuo, Ken N ^g   Wang, Chang Bi ^a   Tsao, Chen Rong ^a,c   Lin, Jaw Town ^f,h  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^h I SHOU UNIVERSITY   (Taiwan)

Author keywords

Acute Coronary Syndrome; Clopidogrel; Proton Pump Inhibitor

Indexed keywords

CLOPIDOGREL; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HAZARD RATIO; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TAIWAN; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; DRUG COMBINATION; GENETICS; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

ACUTE CORONARY SYNDROME; AGED; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TICLOPIDINE;

EID: 77957338399     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.06.067     Document Type: Article

References (27)

1. T.O. Cheng The current state of cardiology in China Int J Cardiol 96 2004 425 439
2. G. Yang, L. Kong, and W. Zhao Emergence of chronic non-communicable diseases in China Lancet 372 2008 1697 1705
3. F.H. Ng, K.F. Lam, and S.Y. Wong Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy Digestion 77 2008 173 177
4. V.P. Tan, B.P. Yan, T.J. Kiernan, and A.E. Ajani Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention Cardiovasc Revasc Med 10 2009 36 44
5. D.L. Bhatt, J. Scheiman, and N.S. Abraham ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use Am J Gastroenterol 103 2008 2890 2907
6. D.L. Bhatt, J. Scheiman, and N. Abraham ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 52 2008 1502 1517
7. B. Giusti, A.M. Gori, and R. Marcucci Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
8. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900
9. J.S. Hulot, A. Bura, and E. Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
10. J.T. Brandt, S.L. Close, and S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
11. D.S. Small, N.A. Farid, and C.D. Payne Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 2008 475 484
12. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
13. P.M. Ho, T.M. Maddox, and L. Wang Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
14. D.N. Juurlink, T. Gomes, and D.T. Ko A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
15. FDA 2009 October 5 http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm Accessed November 25, 2009
16. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
17. P.H. Tseng, Y.C. Lee, H.M. Chiu, H.P. Wang, J.T. Lin, and M.S. Wu A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes J Clin Gastroenterol 43 2009 920 925
18. Y.C. Lee, J.T. Lin, H.P. Wang, H.M. Chiu, and M.S. Wu Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease J Gastroenterol Hepatol 22 2007 1286 1292
19. T.J. Humphries, and G.J. Merritt Review article: drug interactions with agents used to treat acid-related diseases Aliment Pharmacol Ther 13 Suppl 3 1999 18 26
20. S. Furuta, E. Kamada, and T. Suzuki Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole Xenobiotica 31 2001 1 10 (Pubitemid 32337057)
21. V. Serebruany, and S. Goto Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit? Thromb Haemost 101 2009 607 609
22. C.Y. Wu, K.N. Kuo, M.S. Wu, Y.J. Chen, C.B. Wang, and J.T. Lin Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease Gastroenterology 137 2009 1641 1648
23. C.Y. Wu, C.H. Wu, and M.S. Wu A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H. pylori eradication and proton pump inhibitor use Clin Gastroenterol Hepatol 7 2009 427 431
24. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
25. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
26. Q. Zhou, X.M. Yu, and H.B. Lin Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese Pharmacogenomics J 9 2009 380 394
27. M. Man, M. Farmen, and C. Dumaual Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans J Clin Pharmacol 50 2010 929 940